Who we are
GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders.
GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.
GenSight Biologics reminds investors that the company’s lead product candidate, GS010/LUMEVOQ®, currently in clinical development, has not yet formally demonstrated its clinical efficacy and safety. It has not been granted marketing authorization in any jurisdiction and is therefore not available commercially.
The application for named patient early access (AAC) submitted by GenSight Biologics in France is currently being reviewed by the relevant authority – the ANSM – on the basis of the available clinical data.
Solid and advanced portfolio in ophthalmic gene therapy
